// App-Quantinova.ai

e21542 : Contextualizing a single-arm trial of ceralasertib (cer) plus paclitaxel with real-world data (RWD) in patients (pts) with advanced melanoma previously treated with anti-PD-(L)1(PDx) therapies.

Researchers

Presenter

  • Miao Jiang

Principal Investigators

  • Jeeyun Lee

  • Daniel Jackson

  • Simon Smith

  • Sajan Khosla

  • Bienvenu LoembE

  • Emma Dean

  • Claire Smith

Medical Centers

  • AstraZeneca Pharmaceuticals LP, Wilmington, DE, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

  • Early Oncology Clinical Science, R&D Oncology, AstraZeneca, Cambridge, United Kingdom

  • Astex Pharmaceutical, Inc., Cambridge, United Kingdom.

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Secondary liver cancer

  • Melanoma

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Lactate dehydrogenase

Drug/Treatment

  • Paclitaxel

  • Anti-CTLA4

  • taxane

Outcome

  • N/A

Study Design

  • Single Arm

  • Cohort

Phase

  • I

Study Id's

  • NCT02630199

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved